PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
G&A reduction while AGEN shows 24669.48% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
1234.83%
Other expenses change of 1234.83% while AGEN maintains costs. Bruce Berkowitz would investigate efficiency.
115.67%
Operating expenses growth above 1.5x AGEN's 49.24%. Michael Burry would check for inefficiency.
115.67%
Total costs growth above 1.5x AGEN's 49.24%. Michael Burry would check for inefficiency.
719.71%
Interest expense growth above 1.5x AGEN's 0.62%. Michael Burry would check for over-leverage.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
115.67%
Similar other expenses growth to AGEN's 121.98%. Walter Schloss would investigate industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.51%
Tax expense growth 1.25-1.5x AGEN's 103.13%. Martin Whitman would scrutinize strategy.
-133.51%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-132.80%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-132.80%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.